These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Botulinum toxin: the story of its development for the treatment of human disease. Schantz EJ; Johnson EA Perspect Biol Med; 1997; 40(3):317-27. PubMed ID: 9167258 [No Abstract] [Full Text] [Related]
24. Botulinum toxin in warfare. Böni R Curr Probl Dermatol; 2002; 30():101-6. PubMed ID: 12471703 [No Abstract] [Full Text] [Related]
25. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products. Dessy LA; Fallico N; Mazzocchi M; Scuderi N Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763 [TBL] [Abstract][Full Text] [Related]
27. Antibody-induced failure of botulinum toxin type B therapy in de novo patients. Dressler D; Bigalke H Eur Neurol; 2004; 52(3):132-5. PubMed ID: 15479980 [TBL] [Abstract][Full Text] [Related]
28. Learning from the past: historical aspects of bacterial toxins as pharmaceuticals. Pellett S Curr Opin Microbiol; 2012 Jun; 15(3):292-9. PubMed ID: 22651975 [TBL] [Abstract][Full Text] [Related]
29. Evidence on botulinum toxin in selected disorders. Zakin E; Simpson D Toxicon; 2018 Jun; 147():134-140. PubMed ID: 29408357 [TBL] [Abstract][Full Text] [Related]
30. [Botulinum toxin, description and clinical applications in the treatment of the face wrinkles]. Braccini F; Berros P; Belhaouari L Rev Laryngol Otol Rhinol (Bord); 2006; 127(1-2):105-11. PubMed ID: 16886541 [TBL] [Abstract][Full Text] [Related]
32. The story of Clostridium botulinum: from food poisoning to Botox. Ting PT; Freiman A Clin Med (Lond); 2004; 4(3):258-61. PubMed ID: 15244362 [TBL] [Abstract][Full Text] [Related]
33. Pharmacology of botulinum toxin: differences between type A preparations. Rosales RL; Bigalke H; Dressler D Eur J Neurol; 2006 Feb; 13 Suppl 1():2-10. PubMed ID: 16417591 [TBL] [Abstract][Full Text] [Related]
34. Safety of botulinum toxin short interval therapy using incobotulinumtoxin A. Dressler D; Saberi FA J Neural Transm (Vienna); 2017 Apr; 124(4):437-440. PubMed ID: 27747444 [TBL] [Abstract][Full Text] [Related]
35. Botulinum toxin: mechanisms of action. Dressler D; Adib Saberi F Eur Neurol; 2005; 53(1):3-9. PubMed ID: 15650306 [TBL] [Abstract][Full Text] [Related]
36. The evolution of botulinum neurotoxin type A for cosmetic applications. Carruthers J; Carruthers A J Cosmet Laser Ther; 2007 Sep; 9(3):186-92. PubMed ID: 17763029 [TBL] [Abstract][Full Text] [Related]
37. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Dressler D Mov Disord; 2004 Mar; 19 Suppl 8():S92-S100. PubMed ID: 15027060 [TBL] [Abstract][Full Text] [Related]
39. Botulinum toxin therapy: past, present and future developments. Dressler D; Johnson EA J Neural Transm (Vienna); 2022 Jun; 129(5-6):829-833. PubMed ID: 35396965 [TBL] [Abstract][Full Text] [Related]
40. Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations. Schlereth T; Mouka I; Eisenbarth G; Winterholler M; Birklein F Auton Neurosci; 2005 Feb; 117(2):120-6. PubMed ID: 15664565 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]